Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
These Stocks have Potential to gain 40%
The first 6 months in the market has been a nose dive towards bearish territory, but it’s seem to taken a U-turn in July. Despite Friday’s pullback, the monthly gains are solid, almost 5% on the S&P 500 and 7.5% on the NASDAQ, marking a turnaround from the long drop we saw earlier.
The million dollar question in many investor’s mind is, is this turnaround real or just a temporary relief before the dive resumes. That remains to be seen, but either way, even if the market reverts to its bearish trend, there will be opportunities for investors - finding them will be the key to success.
>>Allogene Therapeutics, Inc. (ALLO)<<
The first stock, Allogene Therapeutics, is a biopharmaceutical company pursuing research in cancer immunotherapies, using allogenic chimeric antigen receptor T-cells, or AlloCAR T, to develop new agents for disease treatment. These are purpose-designed precision medicines that work with the patient’s own immune system to attack cancers. The company is at the clinical stage, with several drug candidates undergoing human clinical trials.
In recent news on the clinical front, Allogene’s most advanced candidate, ALLO-501A, received regenerative medicine advanced therapy (RMAT) designation from the FDA, giving the program an expedited status. ALLO-501A’s new designation followed on a positive data release from the ALPHA2 trial, which is testing the drug on patients with relapsed or refractory Large B cell Lymphoma (LBCL). The data showed that AlloCAR T therapies are safe and effective, and produce durable patient responses. The company plans to initiate a Phase 2 pivotal trial this year.
>>>Prometheus Biosciences (RXDX)<<<
The next Goldman pick we’re looking at is another biopharma in the precision medicine niche. Prometheus is working on new treatments for immune-related gastrointestinal conditions, with a focus on inflammatory bowel diseases (IBD). Most of Prometheus’ program is in early, preclinical stages, but the company does have one drug candidate, PRA023, currently undergoing three human clinical trials to treat Ulcerative Colitis, Crohn’s Disease, and Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD). The company uses a biomarker-targeted therapeutic approach, based upon a patient’s biomarker profile. This patient-centric mode offers the promise of transformed patient outcomes.
Prometheus has recently reported several updates to its clinical trial programs of PRA023. First, the company has initiated a third Phase 2 study of the drug candidate, focusing on SSc-ILD. The study was initiated in March of this year, and top line results are expected in 1H24.
>>>Regencell Bioscience (RGC)<<<
An under the radar counter which has a possibility of moonshot is Regencell Bioscience Holding. Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder **(”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
From the latest findings, Regencell Bioscience’s (TCM) treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distrubte the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://finance.yahoo.com/news/buy-2-stocks-jump-40-090447531.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Top Performing IPO Stock Of 2021: $RGC TOP PERFORMER
2021 was the busiest year for deals since 2000, with a record-breaking IPO rush of 1,035 listings in the US, with the biotech and healthcare sectors leading the way, accounting for 36% of all IPO activity.
While most investors are busy reviewing stocks in their current portfolio, it may come as a surprise which company came in first for stock return. Although it is currently not a household name, any savvy investor should definitely keep this stock on their radar: Regencell Bioscience (NASDAQ:RGC). RGC is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
A June 2022 article mentioned that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
RGC’s Solid Foundation
As mentioned above, RGC is closely held by the CEO who owns over 81% of the company. He has used $5.9 million of his personal funds to purchase RGC shares from the open market since its IPO.
His consistent share purchases convey his confidence, commitment and conviction in the company and is putting his money where his mouth is. There are few companies that have the CEO owning this much of the business. The company’s entire management team has also extended the lock-up period of their share options, which shows they are collectively committed to their goal and mission, which is to save and improve lives.
For graphical charts, kindly refer to the site source: https://www.benzinga.com/amp/content/28316977
CEO Holding Majority Share, what does it entail?
Company CEO of Regencell Bioscience Holding (NASDAQ: RGC), Mr Yat-Gai Au has been buying back shares over the year. (over 68.34k shares with average price of $USD 26). The company stock price dropped in last month’s lowest of $USD 28.60 becoming its new support line.
Analyst data recorded that Mr Au’s recent purchase of shares was the biggest made as an insider individual.
That means that an insider was happy to buy shares at above the current price. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares.
As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Yat-Gai Au was the only individual insider to buy shares in the last twelve months.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests.
Regencell Bioscience Holdings insiders own 81% of the company, currently worth about US$260m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
[https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html](https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html)
Early investors of Regencell Bioscience - Spoiler: Individual was also early supporter of Zoom
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen >300% growth since IPO and had seen heavy sell off during period of mid June, however is seen bounced around 40% since the lows in June.
Of course one of the biggest and strongest supporter of the company share is no other than the company ) who believes in a better and brighter future for the company.
The founder and company CEO, (Mr Yat-Gai Au) in supporting of his commitment,confidence and his position towards the company, he has deployed over $5 million dollars of his own personel reservers in buying back company stock to reposition against possible short and distort sellers.
Another prominent early investor of RGC is Mr Samuel Chen, who is a very succesful early **Zoom Video Communications, Inc.** investor (Nasdaq: Zoom). Mr Samuel owned 8.8% of Zoom shares and was the second largest individual investor.
To date, Mr. Au has converted his shareholders’ loan of $3.25 million to Regencell’s ordinary shares upon listing and has pledged not to draw a salary and bonus of more than $1 until Regencell reaches a $1 billion market capitalization and reserved share options for all employees except himself.
In addition, in demonstrating the management’s commitment towards the company, all all directors and employees who were previously granted stock options upon Regencell’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i](https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i)
Share Price movement in Healthcare Company $RGC
The Fed is raising interest rates aggressively in an attempt to tame raging inflation and this has been hurting many stock investors who’s seeing bleeding portfolios on their phone or desktops.
Companies are predicted to slash forecasted earnings in the coming earnings quarter due to the high inflation rates and possible slowdown in earnings.
In an interview with MoneyWise earlier this year, Investor Rick Rule said, “I do not believe that the broad equities market will handle multiple rate hikes.”
Rule doesn’t suggest bailing on stocks completely.
This brings to a healthcare stock which had been recently IPO last year July 22’ which had seen a a good run of 300% capital gains after listing. Shares have taken a heavy hit from short sellers and hedge funds whom had strategically targeting the company stock. However RGC had recovered to the $30s, encouraged by study results for Regencell’s RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder communication, and support for the shares in the market.
The formulae candidates aim to address the fundamental causes of disorders while alleviating symptoms and improving overall health at the same time. Taking a holistic approach, RGC’s TCM uses natural ingredients to treat different elements in the body and every bodily function is taken into consideration when preparing the TCM formulae for patients.
Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
Some highlights about the company executives and founders, showing long term conviction in the company:
- CEO to draw only $1 annual salary and no bonus until the company reaches a $1 billion market capitalization
- CEO to continue company share buyback to demonstrate commitment to the Company and position against short and distort sellers.
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
In the next few months, RGC expects to report data from its second clinical study of its standardized TCM formula for the treatment of ASD and ADHD.
We will then findout if the company has been making positve progress on the company when the report becomes available.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
Want to Ride Out Market Volatility? Diversity into this small cap with high upside!
In recent weeks since market has touched levels that are the low point of the current bear market, there’s been a change in leadership among best performing sectors.
For most of the first half of 2022, the only sector posting gains was energy, with utilities living up to their defensive reputation and posting the smallest losses among the 10 remaining sectors.
But since June 16, technology and consumer cyclical stocks are the leading sectors after being hit harder than the rest of the market in the first half of the year. Stocks leading the bounce include Amazon (AMZN), Tesla (TSLA), Home Depot (HD), and McDonald’s (MCD).
But watchful eyes are looking out on whether it is just a relief rally or a more durable trend.
Good investors should not time the market, but to adapt and rotate based on the market sentiment and trend. Defensive stocks are a recommendation for all cautious investors ie. Healthcare, Utility, F&B and REITS.
A small cap healthcare industry which has not yet reach mainstream media is Regencell Bioscience Holding (RGC).
RGC is an early bioscience healthcare company which focuses on R&D and commercialsation treatment of ASD, ADHD and COV19 using Traditional Chinese Medicine (”TCM”) method.
Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
Some highlights about the company executives and founders, showing long term conviction in the company:
- CEO to draw only $1 annual salary and no bonus until the company reaches a $1 billion market capitalization
- CEO to continue company share buyback to demonstrate commitment to the Company and position against short and distort sellers.
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
This brings to a healthcare stock which had been recently IPO last year July 22’ which had seen a a good run of 300% capital gains after listing. Shares have taken a heavy hit from short sellers and hedge funds whom had strategically targeting the company stock. However RGC had recovered to the $30s, encouraged by study results for Regencell’s RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder communication, and support for the shares in the market.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
Company CEO's Education Background and Achievements
Mr. Yat-Gai Au is the founder and CEO of Regencell. He graduated with a bachelor’s degree from UC Berkeley’s Haas School of Business and began his career in investment banking at Deutsche Bank and ING Barings.
# Education Background and Achievements RGC CEO
Some of his accomplishments in his banking career were completed over US$4 billion worth of deals and won many prestigious M&A awards. Notable deals include the US$750 million acquisition of Philippine Long Distance Telephone, the US$650 million acquisition of Indofood and the US$1.8 billion secondary placement for 40% interest in Hagemeyer, all of which were executed on behalf of First Pacific Company Limited. He is also a founding partner of one of California’s largest group of property investors and an active technology and biotech investor.
Over the years, Yat-Gai has personally seen the amazing recovery of many ADHD and ASD patients using a particular Traditional Chinese Medicine treatment.
He established Regencell in 2015, after witnessing notable improvements in many cases, including close family members who had shown ADHD and ASD symptoms. Yat-Gai is now dedicating his professional efforts and personal funds to bringing the natural formula to patients, families and caregivers around the globe.
Mr Au personnel involvement in his own philanthropic project aims to provide care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties.
As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
Yat-Gai is passionate about participating in and funding charitable activities for the elderly, gifted students and the financially underprivileged in Hong Kong and USA. During the 2020 COVID19 outbreak, he has donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au setup Regencell Foundation Limited to further his charitable endeavors
[https://www.topionetworks.com/people/yat-gai-au-60866c12843bac2b60498b52]
$RGC Small Cap Bioscience/Healthcare Company - ASD, ADHD and COV19 Treatments
Regencell Bioscience Holdings Limited (Nasdaq: RGC) - an early-stage bioscience company that focuses on the Research and Development and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong (where the company is located) and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
The company’s strategy will be to run the research locally in Hong Kong, and to subsequently expand its presence and treatment to other markets as part of their expansion strategy. In the company’s preparation for its future expansion, RGC has formed a JV (”joint venture”) to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
The company CEO, Mr Au has shown deep conviction and believe in his company’s direction and mission. To cement his and the company’s mission, all directors and employees who were granted stock options during the company’s IPO (”Initial Public Offering”) have agreed to a lock-up for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Moreso, Mr Au has declare that he will only receive $1 dollar annual salary and will receive no bonus until the company reaches $1 billion market capitalisation.
https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo
$RGC Small Cap Bioscience/Healthcare Company - ASD, ADHD and COV19 Treatments
Regencell Bioscience Holdings Limited (Nasdaq: RGC) - an early-stage bioscience company that focuses on the Research and Development and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong (where the company is located) and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
The company’s strategy will be to run the research locally in Hong Kong, and to subsequently expand its presence and treatment to other markets as part of their expansion strategy. In the company’s preparation for its future expansion, RGC has formed a JV (”joint venture”) to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
The company CEO, Mr Au has shown deep conviction and believe in his company’s direction and mission. To cement his and the company’s mission, all directors and employees who were granted stock options during the company’s IPO (”Initial Public Offering”) have agreed to a lock-up for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Moreso, Mr Au has declare that he will only receive $1 dollar annual salary and will receive no bonus until the company reaches $1 billion market capitalization.
https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo
Short squeeze Trade on Small Cap Healthcare Counter
Regencell Bioscience Limited’s (NASDAQ:RGC) stock that has seen a good rise of over 300% since taking the company IPO in July 2021. The company is a bioscience **healthcare** company that focuses on heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).
As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
Small Cap Drug Stocks to put in your Watchlist!
The drug/biotech sector has been witnessing developments in pipeline areas like rare diseases, gene therapy and editing, and mRNA vaccines. It is expected that innovation will continue to drive growth in the sector in 2022 with advances expected to be made in areas like Alzheimer’s, cell, gene therapy, mRNA research, treatment of neurodevelopmental disorders and Covid-19 virus.
**Assertio Holdings**
This Lake Forest, IL-based specialty pharma company, which markets neurology, inflammation and pain medications.
Earnings estimates for 2022 have improved from 35 cents per share to 40 cents per share over the past 60 days. The stock has risen 50% this year so far.
Assertio Holdings has undergone a major transformation. Its restructuring is now complete and the company has now shifted focus on growing its business. Assertio Holdings has invested in digital capabilities, resolved several legacy legal uncertainties and set up a new commercial model. The company’s successful execution of its restructuring plan has resulted in significant cost savings, which have boosted its profits despite product sales decline. The company raised its full-year adjusted EBITDA guidance in May, following strong first-quarter results and an optimistic outlook for the rest of the year.
**Regencell Bioscience Holding**
Hong Kong-based company, an early clinical stage bioscience company, founded in 2014, in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
For over a year (Mar 2020 - Aug 2021), RGC has established protocols and procedures for conducting Evaluation and Assessment of RGC-COV19 TCM through a Holistic approach **(EARTH)** efficacy trial in Malaysia and the United States.
The first EARTH efficacy trial (EARTH-A TRIAL) yielded promising results, with mild-to-moderate symptoms eliminated in 97.3% of the 37 patients tested (except for sensory dysfunctional or occasional cough).A trial of Earth-A was conducted with the Delta Variant.
An additional efficacy trial (EARTH-B TRIAL) was also conducted later and followed the same procedures as its predecessor, but on a larger patient scale. In this trial, 80% of the COVID-19 cases were of the Omicron variant for patients gathered in Malaysia.
**Chinook Therapeutics**
This Berkeley, CA-based biotech makes precision medicines for kidney diseases. The stock is up 12.3% this year so far.
Chinook Therapeutics’ lead clinical programmes are atrasentan and BION-1301, which are being developed for IgA nephropathy (IgAN), a serious progressive disease. Data presented from the ongoing phase I/II study of BION-1301 in patients with IgAN have demonstrated durable reductions in mechanistic biomarkers and corresponding proteinuria reductions within three months of initiating treatment. Moreover, Chinook Therapeutics believes that atrasentan, which is in phase III development for IgAN, has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function. Both candidates have been granted orphan drug designation by the European Commission for IgAN.
The stock of Viracta Therapeutics has risen 3.6% this year so far. The consensus loss estimate for 2022 has narrowed from $1.44 per share to $1.24 per share over the past 60 days.
Trending Stocks to Own Right Now!
With inflation worries high, and the Federal Reserve tightening rates aggressively, market action has been challenging so far in 2022.
Remember, there are thousands of stocks trading on the NYSE and Nasdaq. But you want to find the very best stocks right now to generate massive gains.
- Dollar General
With recession looming, even Dollar General shoppers are having to tighten their belts. U.S. consumers, the backbone of economic growth, are not as optimistic these days as they usually are.
Dollar General has struggled to top sales and earnings growth rates it posted during the pandemic. Nevertheless, the company boosted its outlook for the year in its latest quarterly report, as shoppers continue to look for deals to mitigate inflation pain
Dollar General said it expect net sales growth of 10% to 10.5% vs. previous views of about 10%. It raised its same-store sales growth forecast to around 3% to 3.5% compared with its previous expectation of 2.5%.
- Centene
Centene is benefiting from a current uptick among health stocks. It has formed a double-bottom pattern, this time with an ideal entry of 87.44.
However it has been meeting resistance at this level. It could form a handle in a few days, lowering the official entry slightly to 87.08.
The relative strength line has just hit a new high, and it remains on a strong long-term uptrend.
Earnings performance is impressive. It holds an EPS Rating of 93 out of 99. **[Earnings grew by an average of 43%](https://research.investors.com/stock-checkup/nyse-centene-corp-cnc.aspx)** over the past three quarters.
Profits are seen ramping up, with 9% growth seen this year and growth of 13% expected in 2023.
The St. Louis-based company is one of the largest Medicaid-based managed care organizations in the country. While Centene primarily provides health care products and services through Medicaid and Medicare, it also works through private insurers.
- Vertex Pharmaceuticals
In Q2, analysts expect the company to earn $3.54 per share on $2.13 billion in sales. Earnings would rise nearly 14% and sales would increase about 19%, according to FactSet.
The company is testing a replacement for pancreatic cells known as islets. Islet cells help produce insulin, but don't function properly in patients with type 1 diabetes. This leads to dangerous spikes in blood sugar. It's important to note, the program is currently on pause in the U.S. while the Food and Drug Administration reviews dosing information.
- Regencell Bioscience
Another rising healthcare bioscience along side Centene and Vertex Pharmaceuticals.
Hong Kong-based Regencell Bioscience is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
As the company is still in development stage for the TCM treatment for COV19, there isnt much findings available yet except for what the CEO has been pledging.
- Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
- Will not award share options for himself;
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://www.investors.com/research/best-stocks-to-buy-now/?src=A00220]
(https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html)
Shares Buyback by CEO
Company CEO of Regencell Bioscience Holding (NASDAQ: RGC), Mr Yat-Gai Au has been buying back shares over the year (over 68.34k shares with average price of $USD 26). The company stock price dropped in last month’s lowest of $USD 28.60 becoming its new support line.
Analyst data recorded that Mr Au’s recent purchase of shares was the biggest made as an insider individual.
That means that an insider was happy to buy shares at above the current price. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares.
As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Yat-Gai Au was the only individual insider to buy shares in the last twelve months.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests.
Regencell Bioscience Holdings insiders own 81% of the company, currently worth about US$260m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
[https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html]
Invest in Defensive Counter Now! Diversifying Portfolio
The Fed is raising interest rates aggressively in an attempt to tame raging inflation and this has been hurting many stock investors who’s seeing bleeding portfolios on their phone or desktops.
Companies are predicted to slash forecasted earnings in the coming earnings quarter due to the high inflation rates and possible slowdown in earnings.
Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
Some highlights about the company executives and founders, showing long term conviction in the company:
- CEO to draw only $1 annual salary and no bonus until the company reaches a $1 billion market capitalization
- CEO to continue company share buyback to demonstrate commitment to the Company and position against short and distort sellers.
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
Regencell Bioscience : Announces First Half 2022 Management Financial Results - Form 6-K
Regencell Bioscience Limited (Nasdaq: RGC), announced its unaudited interim financial results for the six months ended December 31, 2021.
Some of the important notes are highlighted below,
Recent Developments
Entry into Joint Venture Agreement on September 2, 2021, Regencell Bioscience Limited entered into a joint venture agreement (the "JV Agreement") with Honor Epic Enterprises Limited ("Honor Epic"), a company incorporated in the British Virgin Islands, to form a joint venture under the laws of Hong Kong.
Operation Expenses
During the six-month period ended December 31, 2021, we incurred total operating expenses of approximately $3.7 million, an increase of approximately $3.3 million, or 893%, as compared to total operating expenses of approximately $0.4 million during the six-month period ended December 31, 2020
General and administrative expenses increased by approximately $2.4 million, or 2,106%, to approximately $2.5 million for the six-month period ended December 31, 2021 from approximately $0.1 million for the six-month period ended December 31, 2020. The increase was mainly attributable to
(i) approximately $1.0 million in amortization of share based payments for our general and administrative personnel for the six-month period ended December 31, 2021,
(ii) approximately $0.5 million increase in professional fees, such as legal services and public relations services as we became a public company listed on the Nasdaq Capital Market,
(iii) approximately $0.4 million increase in salaries due to the increase in the number of staff and bonus payments during the six-month period ended December 31, 2021,
(iv) approximately 0.3 million increase in rental expenses due to the rental of new office and staff quarters,
(v) approximately 0.2 million increase in traveling and entertainment and others mainly due to more business activities since our operation expanded during the six-month period ended December 31, 2021
Other Income, Net
Total other income, net was approximately $100 for the six-month period ended December 31, 2021 and total other income, net was approximately $35,000 for the six-month period ended December 31, 2020.
Other income mainly consisted of cash received from a government grant and interest income. Other income decreased to approximately $100 for the six-month period ended December 31, 2021 from approximately $35,000 for the six-month period ended December 31, 2020, because the Company did not receive any government grants in respect of COVID-19-related subsidies from the Employment Support Scheme provided by the Hong Kong Government under the Anti-Epidemic Fund during the six-month period ended December 31, 2021
Cash
As of December 31, 2021, we had cash of approximately $19 million compared to approximately $0.06 million as of June 30, 2021. The increase of cash was mainly due to the receipt of net IPO proceeds from the completion of our IPO in July 2021. The net proceeds of the IPO, including proceeds from the sale of Over-allotment Shares, totaled approximately $22.7 million, after deducting underwriting discounts and other related expenses of approximately $2.3 million.
[https://m.marketscreener.com/quote/stock/REGENCELL-BIOSCIENCE-HOLD-124803353/news/Regencell-Bioscience-Announces-First-Half-2022-Management-Financial-Results-Form-6-K-40625825/]
Small Cap - Healthcare Stock - RGC - Moonshot Potential!!
Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell Bioscience’s (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distrubte the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Insiders Percentage and they have not stop buying / $RGC
In investing, it is always worth while to find out who are the majority shareholders of the company. Understanding of business ownership structure is vital as it determines who is in control of the company and its direction. Moreso, having a large number of shares would either benefit or loses most when the stock price moves.
Data shows that insiders recently bought shares in the company and they were rewarded after market cap rose US$64m last week.
Small companies that are not very actively traded often, thus lack institutional investors. It is more common to see institutional investors in larger companies instead.
There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company. Alternatively, there might be something about the company that has kept institutional investors away.
Hedge funds don't have many shares in Regencell Bioscience Holdings. With a 81% stake, CEO Yat-Gai Au is the largest shareholder. It's usually considered a good sign when insiders own a significant number of shares in the company, and in this case, it’s glad to see a company insider with such skin in the game. In comparison, the second and third largest shareholders hold about 7.6% and 0.1% of the stock.
With a 11% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Regencell Bioscience Holdings. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
With a stake of 7.6%, private equity firms could influence the Regencell Bioscience Holdings board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
[https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings/news/regencell-bioscience-holdings-limited-nasdaqrgc-insiders-hav]
Investors should turn to Healthcare Defensive Stocks to Weather This Current Sentiment
U.S. stocks extended losses at Tuesday's open as investors mulled disappointing earnings from Walmart and General Motors and braced for results from Big Tech due out after the bell.
The benchmark S&P 500 tumbled 0.6%, while the Dow Jones Industrial Average declined by roughly 100 points, or 0.3%. The technology-heavy Nasdaq Composite fell 1.1%.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell bioscience, a healthcare company stock was also affected by the market, seeing drops of around 30% from last week’s peak. Investors who are looking to own this stock could find the current price attractive and begin collecting the ticker.
Regencell is a recently IPO in July 2021, and had seen a staggering rise of >300% in share price weeks after being listed.
Regencel Bioscience Holding is a R&D and Commercialize Healthcare company that focusses on treating ADHD, ASD and COVID-19 using Traditional Chinese Medicine (”TCM”) approach.
In the past, the company had been through rainy and rough days of being shorted by both short sellers and traders alike which had been strategically planned. Some journalists even compared the short attacked to be identical or even more severe than what happened to the infamous GameStop (GME)
The Company CEO, a practicing TCM practitioner (Mr Au) did not taken this event without a stand. Mr Au has voiced out “Short and distort schemes used on our stock are negatively affecting our company. These schemes hurt our investors and patients, especially children and their families who are looking for a natural approach to treat attention hyperactivity disorder (“ADHD”), autism spectrum disorder (“ASD”) and COVID-19, and have the potential to disrupt our mission to help our patients.”
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Mr Au took further response by buying back over 5 million ordinary shares to defend the company against these short sellers and has also announced that he will not be drawing salary nor bonus (<1$) until the company reaches $1 Billion USD.
Further stance were taken by the company’s directors and employees where stock options which were previously granted upon company IPO will be subjected to a lock-up of 6 months vesting period. The shares will be locked up until January 16, 2023.
$RGC Regencell Bioscience Low-float biotech has seen selling dry up to nothing. An influx of volume combined w/a short position & tightly held shares (88% insider controlled)
Regencell Bioscience $RGC Low-float biotech has seen selling dry up to nothing. An influx of volume combined w/a short position & tightly held shares (88% insider controlled) could send shares on a strong run! Med/bio = great recession sector. #shortsqueeze $GME $AMC $APE $IBB pic.twitter.com/1gHiWlz3ld
— Hedgehog Trader 🦔 (@HedgehogTrader) November 29, 2022
Small Cap Medical Stock, treating ASD, ADHD and COV19
Regencell Bioscience Holdings Limited (Nasdaq: RGC) - an early-stage bioscience company that focuses on the Research and Development and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder **(”**ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong (where the company is located) and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
The company’s strategy will be to run the research locally in Hong Kong, and to subsequently expand its presence and treatment to other markets as part of their expansion strategy. In the company’s preparation for its future expansion, RGC has formed a JV (”joint venture”) to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
The company CEO, Mr Au has shown deep conviction and believe in his company’s direction and mission. To cement his and the company’s mission, all directors and employees who were granted stock options during the company’s IPO (”Initial Public Offering”) have agreed to a lock-up for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Moreso, Mr Au has declare that he will only receive $1 dollar annual salary and will receive no bonus until the company reaches $1 billion market capitalization.
Choose Defensive Stock for Volatile Market
# Defensive Stance in Downtrend Market : Regencell ($RGC)
The past months of market volatility has not been kind to many tech and growth sector stocks which has seen large drops between 30-50%. The recent beatdown of these sectors are mainly due to the market uncertainty of growing inflation numbers, quantitative easing of Fed's reserve, Russian-Ukraine War and rise in oil pricing.
The market has diverted its attention from the growth sector and into defensive sectors ie. healthcare, utilities and consumer staple; which are less volatile and less sensitive to the economic cycle. The simple understanding is that these sectors fall under human essential services, necessary for any day to day affair.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The company's CEO (Mr. Yat-Gai Au), since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
$RGC Defensive Stock to include in your Portfolio (HEALTHCARE)
Investors and traders alike has seen stock market and crypto market tanked in the past several months due to multiple black swan events ie. Russian-Ukraine War, Fall of Luna/Terra, US Rate hikes, Surge in oil price, and amongst other things, INFLATION.
During this bear market, majority of stock companies and crypto prices have tank-ed, but there is a company that is currently showing resilience and is on an uptrend.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD and ASD, and infectious diseases targeting people’s immune system ie. COVID.
The stock price has seen 300% growth since IPO. The stock price has seen days of being shorted by traders in recent months. We will be monitoring these next few days if the stock price will rally to its previous ATH again.
The company's CEO (Mr. Yat-Gai Au), since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
A Strong Management Company for Your Watchlist $RGC
A company with strong financials is crucial. However, a company with strong leadership and management is equally as critical to the long term growth of a company.
When investors look for a company, the quantitative aspect is usually sought-after (ie. profit growth, cash flow, debt, etc) as the primary focus. However the qualitative (company leadership and management), nature of the company should also be taken into consideration. Qualitative assets are usually harder to detect as they are not quantifiable but numbers and figures.
Examples of successful companies with strong qualitative are like META (previously Facebook).
Meta grew as it holds appeal to the public and has been smart about acquiring businesses and recruiting/retaining talents. The CEO’s efforts (Mark Zuckerberg) also grin up near-term revenue prospects with its push into TV-like contents.
Presently, we take a look at a defensive healthcare company (RGC) Regencell Bioscience Ltd. A company focusing on using Traditional Chinese Medicine to treat ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
Since listing, the company CEO has purchased over $5 MIL of ordinary shares and has yet to sold any as of today. This qualitative aspect of the company displays the company and managements confidence and conviction about the company’s direction and future.
Moreso, the CEO will continue to deployed personnel funds buying back shares all against the market shorters and sellers.
The company has a prominent investment backer, Samuel Chen, who had a significant position in ZOOM (8.8% holding) post-IPO and Zoom’s market capitalization peaked at US$161 billion on 19 October 2020.
Investors should always remember to look into the qualitative face of the company, as it does play a part in identifying the strength of the company.
[https://money.usnews.com/investing/articles/2017-06-12/10-of-the-best-managed-public-companies]
$RGC Healthcare Stock for your watchlist - Using Traditional Chinese Medicine (TCM) Method
Regencell Bioscience Holdings Limited (Nasdaq: RGC) a bioscience company focusing on treatment using Traditional Chinese Medicine (”TCM”) on neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19. The company is mainly focusing on both R&D of these treatments and also commercialization of the medicine once conclusive results are met.
In latest findings, Regencell Bioscience’s (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distrubte the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
$RGC Potential Bagger healthcare Company - HOT STOCK -
Regencel Bioscience Holding is a R&D and Commercialize Healthcare company that focusses on treating ADHD, ASD and COVID-19 using Traditional Chinese Medicine (”TCM”) approach.
The company’s stock has seen rough days of being shorted by both short sellers and traders alike and the Company CEO has not taken this event without a stand. Mr Au, the CEO of Regencell has voiced out “Short and distort schemes used on our stock are negatively affecting our company. These schemes hurt our investors and patients, especially children and their families who are looking for a natural approach to treat attention hyperactivity disorder (“ADHD”), autism spectrum disorder (“ASD”) and COVID-19, and have the potential to disrupt our mission to help our patients.”
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Mr Au took further response by buying back over 5 million ordinary shares to defend the company against these short sellers and has also announced that he will not be drawing salary nor bonus (<1$) until the company reaches $1 Billion USD.
Further stance were taken by the company’s directors and employees where stock options which were previously granted upon company IPO will be subjected to a lock-up of 6 months vesting period. The shares will be locked up until January 16, 2023.
$RGC Online Interview sharing outcome of TCM's Treatment
Regencell Bioscience Limited is a Hong Kong company which is fronting the uses of Traditional Chinese Medicine (”TCM”) to treat not only ADHD and ASD but also Covid-19 which shook the world back in 2020.
Regencell is currently a listed Company in NASDAQ market in the US with its ticker $RGC.
At present, RGC has treatment formula has test treated 19 patients (suspected or confirmed COVID cases). 12 of 19 patients which were treated exhibited improvements in their recovery after an average treatment period of 5 days.
An interview was held on SSN Network (The Official Small-, Micro- and Nano-Cap News Source™) which included Jay Lee, CEO of Regencell Bioscience Asia Limited, and Paul Niewiadomski, Independent Director; where they talk about the company, the procedures and protocols of their treatments and result findings.
[https://finance.yahoo.com/news/regencell-describes-traditional-chinese-medicine-133000084.html]
Separately, while Mr Au, the company’s CEO and chairman was not included as part of the interview, he has been working in in the background in defending his company from the recent short seller and trader attacks on the company stock. Mr Au has bought back over $5 Million Dollars of company share since taking the company IPO.
Mr Au has mentioned “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
Aside from the company’s positive progress in medical, the CEO (Mr Au) has shown his confidence in the progress of the company direction and not sold a single share since taking his company to Initial Public Offering (”IPO”) in Year 2020. Mr Au has pledged to not take salary and bonus (<1$) until the company reaches US$1 Billion market cap as his target.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
Company CEO Stepping Up in Shutting down Short Sellers and Hedge Funds
CEO of Regencell Bioscience Holdings has voiced out against traders who are shorting and putting out negative schemes on the company stock, negatively impacting the company’s image.
Regencell Bioscience Holdings (RGC: Nasdaq) is a an early-staged bioscience healthcare company focusing on R&D and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
These negative schemes have indirectly put harm to RGC investors and patients whom rely on the company’s developments to develop a natural approach towards treatment of Attention Hyperactive Disorder (ADHD) Autism Spectrum Disorder (ASD) and Covid-19.
RGC’s CEO (Mr Yat-Gai Au) has agreed to continue draw 1$ annual salary and with no bonuses until the company has reached $1 Billion market cap and reserve share options for all employees except himself. He has even pledged to continue putting personal funds to buyback company shares to display his commitment to the company and his stances against short sellers.
More so, to further demonstrate the company’s commitment, all directors and employees who were granted with stock options during IPO have agreed to a 6 months lockup after it is vested. These stocks options will be vested on July 16th 2022, hence it will remain locked until Janurary 16th 2023.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
$RGC - A company with Strong leadership that puts money where his mouth is!
A company with strong financials is crucial. However, a company with strong leadership and management is equally as critical to the long term growth of a company.
When investors look for a company, the quantitative aspect is usually sought-after (ie. profit growth, cash flow, debt, etc) as the primary focus. However the qualitative (company leadership and management) nature of the company should also be taken into consideration. Qualitative assets are usually harder to detect as they are not quantifiable but numbers and figures.
Examples of successful companies with strong qualitative are like META (previously Facebook).
Meta grew as it holds appeal to the public and has been smart about acquiring businesses and recruiting/retaining talents. The CEO’s efforts (Mark Zuckerberg) also grin up near-term revenue prospects with its push into TV-like contents.
Presently, we take a look at a defensive healthcare company (RGC) Regencell Bioscience Ltd. A company focusing on using Traditional Chinese Medicine to treat ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
Since listing, the company CEO has purchased over $5 MIL of ordinary shares and has yet to sold any as of today. This qualitative aspect of the company displays the company and managements confidence and conviction about the company’s direction and future.
Moreso, the CEO will continue to deployed personnel funds buying back shares all against the market shorters and sellers.
The company has a prominent investment backer, Samuel Chen, who had a significant position in ZOOM (8.8% holding) post-IPO and Zoom’s market capitalization peaked at US$161 billion on 19 October 2020.
Investors should always remember to look into the qualitative face of the company, as it does play a part in identifying the strength of the company.
https://money.usnews.com/investing/articles/2017-06-12/10-of-the-best-managed-public-companies
$RGCis embracing to improve the lives of the millions dealing with Attention Deficit Hyperactive Disorder (ADHD) and Autism Spectrum Disease (ASD) and an approach that has shown some encouraging improvements that sufferers of these conditions and their families are likely to be interested in.
Regencell Bioscience (RGC) is an early-stage bioscience company that focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD. Before getting into the specific applications for ADHD and ASD, the TCM approach to addressing health issues may be somewhat unknown to those of us in the west and it would be helpful to understand the big picture before drilling down to the specifics. According to the National Institute of Health, TCM uses various psychological and/or physical approaches as well as herbal products to address health problems, examples of these approaches include:
• Tai Chi
• Acupuncture
• Herbal Products
Johns Hopkins Medicine notes that the basic concept behind TCM is that a vital life force, called Qi, surges through the body. Any imbalance to Qi can cause disease and illness. This imbalance is most commonly thought to be caused by an alteration in the opposite and complementary forces that make up the Qi. These are called yin and yang. Getting a little more specific in TCM, the functions of the brain are dispersed to five zang organs, and are maintained by comprehensive functional interactions among the five zang organs. Therefore, brain diseases such as ASD and ADHD are regarded as systematic diseases in TCM, and their treatments are aimed to normalize not only the activity of the organs, but also the balance of functional interaction.i
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial
https://finance.yahoo.com/news/regencell-bioscience-standardized-formulae-shown-131500297.html
$RGC Experts tell us how they assess management and why they think these companies have good leadership.
https://money.usnews.com/investing/articles/2017-06-12/10-of-the-best-managed-public-companies
HIDDEN GEM STOCK - $RGC Regencell Bioscience Business and its CEO
Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong (where the company is located) and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
The company’s strategy will be to run the research locally in Hong Kong, and to subsequently expand its presence to other markets as part of their expansion strategy. In the company’s preparation for its future expansion, RGC has formed a JV (”joint venture”) to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
The company CEO, Mr Au has shown deep conviction and believe in his company’s direction and mission. To cement his and the company’s mission, all directors and employees who were granted stock options during the company’s IPO (”Initial Public Offering”) have agreed to a lock-up for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Moreso, Mr Au has declare that he will only receive $1 dollar annual salary and will receive no bonus until the company reaches $1 billion market capitalization.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
JUICY SHORT SQUEEZE PLAY HERE BOYS $GME $RGC
Fellow Redditors of r/wallstreetbets took Wall Street by storm when they rally against hedge funds and showing the high and mighty folks in fancy suits who’s the boss by short squeezing $GME (GameStop) stock. The stock of GME reached a premarket value of over $500 per share. The price was nearly 30 times the $17.25 valuation at the beginning of January 2021; putting big losses to hedge funds and also sending some of them packing (filed for bankrupcy).
A similar potential is seen in $RGC Regencell Bioscience Holdings where the short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year.
Moreso, Regencell found to be shorted occasional days close to 90%, higher than GameStop.
Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price.
Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52.
Little is known if there will be any short squeeze happening on RGC but it is something aggresive or awared traders could keep in their watchlist.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
$RGC Price History #Nasdaq Mover https://www.barchart.com/stocks/quotes/RGC/price-history/historical
$RGC HUGE Shortsqueeze potential on Healthcare Counter
Regencell Bioscience Limited’s (NASDAQ:RGC) stock that has seen a good rise of over 300% since taking the company IPO in July 2021. The company is a bioscience **healthcare** company that focuses on heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).
As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
For Short volume available, to look up at https://fintel.io/ss/us/rgc#
$RGC, a long lost twin of GME? - Shortsqueeze potential!!
Regencell Bioscience Limited’s (TICKER: RGC) stock is an undiscovered short squeeze potential. The short volume ratio has similar pattern as that of GameStop Corp. (TICKER: GME), whereby both averaged over 40% in the past year. In fact, RGC is more heavily shorted than GME as some days were close to 90% shorted.
However, as much as RGC and GME stock’s short volume profile is similar, not much is known about the facts and figures of RGC, which is provided below. As of 16 May 2022, RGC’s founder and CEO holds 10,539,159 ordinary shares, representing 81.0% of the total number of issued and outstanding ordinary shares in RGC. RGC’s total cumulative short volume as reported by third party data analytics provider is over 19 million shares and RGC’s total reported short volume to outstanding shares (excluding CEO and Chairman ownership ratio) is over 7 times, which is almost double that of GME. Where are all the extra shares coming from?
A short squeeze on GME created a return of 51x (current price to its historical low) to 191x (historical high to its historical low), what is the potential for RGC if there is a short squeeze?
https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/
RGC Founder; Yat-Gai Au, Just Bought A Few More Shares
Those following along with Regencell Bioscience Holdings Limited will no doubt be intrigued by the recent purchase of shares by Yat-Gai Au, Founder of the company, who spent a stonking US$1.2m on stock at an average price of US$25.23. While that only increased their holding size by 0.5%, it is still a big swing by our standards.
Regencell Bioscience Holdings Insider Transactions Over The Last Year
In fact, the recent purchase by Yat-Gai Au was the biggest purchase of Regencell Bioscience Holdings shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at above the current price of US$24.86. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Yat-Gai Au was the only individual insider to buy shares in the last twelve months.
Yat-Gai Au purchased 68.34k shares over the year. The average price per share was US$26.03. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below.
https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html
Regencell Bioscience ( $RGC ) Gallery View see here - https://stockcharts.com/freecharts/gallery.html?RGC
$RGC on zacks News: Forging A New Approach To ADHD And ASD
https://scr.zacks.com/news/news-details/2022/RGC-Forging-a-New-Approach-to-ADHD-and-ASD/default.aspx
$RGC Is Developing A Breakthrough Approach To ADHD And ASD
Traditional “western” medicine has made amazing advances and is one of the great innovations in history, but, unfortunately, there are still many conditions afflicting people that western medicine hasn’t been able to treat with any great effectiveness. It’s in instances like these that it can be beneficial to look to a medical approach that’s been around for over 2,000 years—a practice known as Traditional Chinese Medicine (TCM). It’s this approach that Regencell (NASDAQ:RGC) is embracing to improve the lives of the millions dealing with Attention Deficit Hyperactive Disorder (ADHD) and Autism Spectrum Disease (ASD) and an approach that has shown some encouraging improvements that sufferers of these conditions and their families are likely to be interested in.
The market that Regencell is attempting to address is even larger as they are likely to enter the Chinese and Hong Kong markets as well. One interesting difference to pay attention to as Regencell moves forward is that a treatment such as this can enter the US market as a nutritional product and therefore requires no governmental approval, reducing the barriers to entry in the US. In China and Hong Kong, however, a Proprietary Chinese Medicine (PCM) designation is needed for the product to be sold, a situation the company is well versed in and will pursue as the treatment gets closer to being ready for commercialization.
The company just completed the second efficacy trial, which was designed to evaluate and assess the effectiveness of Regencell’s standardized TCM formula in reducing ADHD and ASD symptoms during the course of a 3-month treatment. The trial is a non-blinded efficacy trial and patients in the trial were between 6 and 12 at the time of the treatment and clinically diagnosed with ADHD and/or ASD. The program required all patients to stop their existing medications, attend weekly treatment sessions with their parents, and follow the TCM Practitioner’s dietary guidelines during the 3-month treatment. Regencell selected 7 children (6 males and 1 female) to participate in the trial. 3 of the patients were diagnosed with ADHD and 4 of them with ASD.
The first results from this trial were just released and showed encouraging improvements. When dealing with these conditions, the company used three different methods to measure improvement:
• SKATBT-A3—48-item questionnaire designed and developed by Regencell to evaluate the effectiveness of a treatment in improving ADHD and ASD patients’ symptoms. SKATBT-A3 assesses a patient’s overall physical and neurodevelopmental conditions. SKATBT-A3 includes elements that are conditions of patients usually observed during TCM treatments such as: (i) speech/language/communication; (ii) patients’ sociability; (iii) sensory/cognitive awareness; and (iv) physical health and behavior.
• VADRS—a tool commonly used to measure ADHD severity.
• ATEC—The ATEC was designed as a comparative subscale for ASD diagnosed individuals – that is to measure change in ASD individuals due to various interventions by difference between the initial (baseline) ATEC scores and later ATEC scores.
All patients orally consumed the standardized TCM formula twice daily for 3 months. Improvements in patients’ symptoms were assessed weekly during treatment review sessions with the TCM Practitioner and the children’s parents.
And here’s the exciting part, after three months, the SKATBT-A3 scores of all patients were lower, indicating fewer problems and improvements in symptoms. According to the company, there were noticeable improvements in the patients’ overall health, ADHD symptoms and ASD symptoms. Common improvements noted included better sleep quality, reduced temper, better bowel movement and healthier complexion. The most notable improvement was demonstrated by two patients who gained the ability to control their tongues naturally without the aid of their own hands after the 3-month treatment. According to company management, this development is noteworthy because limited tongue function affects verbal communications and language abilities.
Improvement was also seen in the measures not designed by Regencell, with the VADRS scores of five patients coming in lower, indicating fewer problems and improvements in symptoms, while one patient’s score remained the same and one patient’s score was higher. Percentage improvements of patients ranged between -21% and 62%, with a mean of 21%. Additionally, the ATEC scores of all patients were lower, indicating fewer problems and improvements in symptoms. Percentage improvement of all patients ranged between 4% and 52%, with a mean of 22%. The company provided some color on the ATEC results and noted that they saw the most significant drop in scores in the health/physical/behavior subscale. Constipation, sleeping problems, poor appetite, anxiety/fearfulness, and irritability are common issues among ADHD and ASD patients and according to Regencell most of the patients suffered from these symptoms before the treatment but these symptoms improved after the treatment.
Importantly, none of the patients experienced any adverse side effects after the 3-month treatment. Additionally, while no guarantees can be made, herbal TCM treatments have an accumulating effect, meaning that while the greatest gains may be seen during the initial months of treatment, progress can be expected to continue the longer treatment is maintained.
While these are trials and there are no conclusions yet, the results seen so far warrant attention and we recommend investors to continue to monitor Regencell’s updates and developments. We are excited for the potential impact and market opportunity of the treatment.
https://scr.zacks.com/news/news-details/2022/RGC-Forging-a-New-Approach-to-ADHD-and-ASD/default.aspx
RGC's own foundation and efforts to treating ADHD, ASD and Alzheimers
Founded in 2017, the Regencell Foundation is a nonprofit organization dedicated to providing assistance to children with ADHD and ASD, and elderly people with dementia, particularly those who are facing financial difficulties.
ADHD and ASD is a neurodevelopmental disorder characterized by impaired social interaction, challenges in verbal and non-verbal communication, and restricted and repetitive behavior. There are more than 383 million people diagnosed with ADHD and ASD globally. The foundation aims to improve the lives of children during their critical stages of development and to help them become independent to lead a normal life.
Alzheimer’s disease, the most common form of dementia, is a growing public health crisis. According to Alzheimer’s Disease International, 46.8 million people worldwide were living with dementia in 2015 and that number is expected to double every 20 years. Our mission is to reduce the burden on caregivers and their families and allow the elderly to live life with dignity.
We have supported and sponsored many charitable organizations in the past and will continue to do so in the future. For example, we have partnered with Community CareAge Foundation (CCAF) to provide dementia assessment and diagnosis, as well as financial aid.
More recently during the COVID outbreak in 2020, we have been donating masks, grocery vouchers, and hand sanitizers to The Neighborhood Advice Action Council (NAAC), a non-profit organization which lends a hand in the densely populated and deprived districts to provide consultation and counselling services to residents of all sectors.
Regencell Foundation is established by Regencell Bioscience Holding ($RGC) which is a small cap stock listed on the Nasdaq Market last year 2021. The company was founded by Mr Au Yat-Gai, whom is CEO and also a practicing Traditional Chinese Medicine practitioner himself.
Aside from works performed by the Regencell Foundation, the owner of RGC, Mr Au is also been involved in his own philanthropic project (within his own means) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
https://www.regencellbioscience.com/regencell-foundation/
$RGC: @RegencellBio Zacks Small Cap Research Forging A New Approach To ADHD And ASD - https://bit.ly/rgc111522
$RGC CEO, Mr Yat-Gai Au said he agreed with $TSLA CEO Elon Musk that sophisticated hedge funds are using short-selling and complex derivatives to take advantage of small investors.
“I will continue to draw a $1 annual salary and no bonus until the company reaches a $1 billion market capitalization and reserve share options for all employees except myself,” Mr. Au said.
He pledged to continue to use his funds to purchase company shares to demonstrate his commitment to Regencell and his position against short and distort sellers.
With a total cumulative short volume of over 19 million shares since the company’s initial public offering (IPO), Mr. Au says he began his share purchases last year using his personal funds to further the company’s goal to save and improve lives.
Additionally, company directors and employees who were previously granted stock options upon the company’s IPO have agreed to a further lockup undertaking for six months after their stock options become vested.
Since Regencell's incorporation in October 2014 up to the IPO, Mr. Au has fully funded the company. Upon the IPO, his $3.25 million loan to the company was converted into approximately 342,000 common shares at an initial offering price of $9.50.
As we are going through an unprecedented time, people are trying to find innovative ways to reshape the world in a positive way. Mr. Au and Regencell have been practicing good corporate social responsibility (CSR) and are working towards an ESG framework by integrating its business and employees’ personal values to create a sustainable business for the future.
Mr. Au's and the company's philanthropic endeavors have not gone unnoticed. His idea is simple: perseverance to do social good and surround yourself with like-minded individuals will inevitably create a successful company, and that starts with hiring the best people who contribute to society and share the same values, where their actions count and views matter.
https://www.benzinga.com/general/biotech/22/11/29658800/from-providing-grants-to-over-10-000-children-with-adhd-asd-and-covid-19-to-building-a-company-to
Penny Stocks Of Companies Working On Long Covid
There are a number of small companies are working on long Covid treatments.
More than four in survey of 10 people said that they knew someone with long Covid, a condition where symptoms persist for several weeks or longer.
Long Covid is particularly complicated because there's no set list of symptoms. The Centers for Disease Control and Prevention notes a wide array of ongoing health problems (https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html) that could include fatigue, shortness of breath, neurological and digestive symptoms as well as joint or muscle pain.
But so far, large companies are shying away from treating the condition.
Instead, small companies have taken up the mantle in long Covid treatment. They include Axcella Therapeutics (AXLA), First Wave BioPharma (FWBI), Ampio Pharmaceuticals (AMPE), Regencell Bioscience (RGC), Aim ImmunoTech (AIM), Tonix Pharmaceuticals (TNXP) and privately held Humanetics.
Hong Kong-based Regencell Bioscience is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
The company’s formula aims to treat the core causes of disorders while reducing the symptoms and improving overall health of its patients at the same time. The direction of using natural ingredients (herbs) to treat elements in the body is taken as the company’s holistic approach toward the treatment process while preparing the TCM formulae for its patients.
(https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/)
Success of Regencell Bioscience #RGC and the man at the helm
Mr. Yat-Gai Au is the founder and CEO of Regencell. He graduated with a bachelor’s degree from UC Berkeley’s Haas School of Business and began his career in investment banking at Deutsche Bank and ING Barings.
Some of his accomplishments in his banking career were completed over US$4 billion worth of deals and won many prestigious M&A awards. Notable deals include the US$750 million acquisition of Philippine Long Distance Telephone, the US$650 million acquisition of Indofood and the US$1.8 billion secondary placement for 40% interest in Havemeier, all of which were executed on behalf of First Pacific Company Limited. He is also a founding partner of one of California’s largest group of property investors and an active technology and biotech investor.
Over the years, Yat-Gai has personally seen the amazing recovery of many ADHD and ASD patients using a particular Traditional Chinese Medicine treatment.
He established Regencell in 2015, after witnessing notable improvements in many cases, including close family members who had shown ADHD and ASD symptoms. Yat-Gai is now dedicating his professional efforts and personal funds to bringing the natural formula to patients, families and caregivers around the globe.
Mr Au personnel involvement in his own philanthropic project aims to provide care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties.
As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
Yat-Gai is passionate about participating in and funding charitable activities for the elderly, gifted students and the financially underprivileged in Hong Kong and USA. During the 2020 COVID19 outbreak, he has donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au setup Regencell Foundation Limited to further his charitable endeavors.
From offering grants to over 10,000 children with ADHD, ASD, and COVID-19 to establishing a company dedicated to saving and improving lives, this CEO may be taking philanthropy to a new level.
Over the years, Mr. Au says he has witnessed patients recover from attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) through TCM treatments. He wondered why such beneficial treatments are only available to a small number of patients and believed that the formula should be more readily available in order to help people around the world.
He established Regencell in 2014 after seeing notable improvements in many cases, including close friends and family members who had shown ADHD and ASD symptoms.
Giving Back
Regencell CEO says he is passionate about participating in and funding charitable activities for the elderly, gifted students and the financially underprivileged. In 2017, he established Regencell Foundation to be able to give back to society. He was taught at an early age that giving back is one of the most fulfilling thing one can do to make the world a better place.
In 2020, during the early-days of the COVID-19 outbreak when face mask were scarce, he sourced and donated over 200,000 masks to hospitals, the elderly and needy families in Korea, Singapore, Vietnam, Malaysia, Hong Kong and the U.S.
Mr. Au also disclosed that he is spearheading a philanthropic project to provide grants to over 10,000 children afflicted with ADHD, ASD, COVID-19 and those in severe financial distress.
“I started providing grants on April 16, 2022, and have already helped over 200 children,” he said.
https://www.benzinga.com/general/biotech/22/11/29658800/from-providing-grants-to-over-10-000-children-with-adhd-asd-and-covid-19-to-building-a-company-to
GME's Twin Brother Squeeze Play
Fellow redditors of r/wallstreetbets took Wall Street by storm when they rally against hedge funds and showing the high and mighty folks in fancy suits who’s the boss by short squeezing $GME (GameStop) stock. The stock of GME reached a premarket value of over $500 per share. The price was nearly 30 times the $17.25 valuation at the beginning of January 2021; putting big losses to hedge funds and also sending some of them packing (filed for bankruptcy).
A similar potential is seen in $RGC Regencell Bioscience Holdings where the short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year.
More so, Regencell found to be shorted occasional days close to 90%, higher than GameStop.
Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price.
Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52.
Little is known if there will be any short squeeze happening on RGC but it is something aggressive or awarded traders could keep in their watchlist.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
Who Is Yat-Gai Au?
After graduating with a bachelor’s degree from the University of California, Berkeley’s Haas School of Business, Mr. Au began his career in investment banking at Deutsche Bank AG and ING Barings.
He has completed deals valued at more than $4 billion and won many prestigious merger and acquisitions (M&A) awards, according to reports.
Notable deals include the $750 million acquisition of Philippine Long Distance Telephone — now PLDT Inc. ADR , the $650 million acquisition of Indofood and the $1.8 billion secondary placement for 40% interest in Hagemeyer — all executed on behalf of First Pacific Company Limited (HKG: 0142).
https://www.benzinga.com/general/biotech/22/11/29658800/from-providing-grants-to-over-10-000-children-with-adhd-asd-and-covid-19-to-building-a-company-to
$RGC Who Is Yat-Gai Au?
After graduating with a bachelor’s degree from the University of California, Berkeley’s Haas School of Business, Mr. Au began his career in investment banking at Deutsche Bank AG and ING Barings.
He has completed deals valued at more than $4 billion and won many prestigious merger and acquisitions (M&A) awards, according to reports.
Notable deals include the $750 million acquisition of Philippine Long Distance Telephone — now PLDT Inc. ADR , the $650 million acquisition of Indofood and the $1.8 billion secondary placement for 40% interest in Hagemeyer — all executed on behalf of First Pacific Company Limited (HKG: 0142).
Traditionally Treating ADHD, ASD & COV19 via Traditional Chinese Medicine (”TCM”) - Small Cap Stock
Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell Bioscience’s (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
374
|
Created
|
02/07/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |